Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206


Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.

Jentzen W, Schneider E, Freudenberg L, Eising EG, Görges R, Müller SP, Brandau W, Bockisch A.

Nucl Med Commun. 2006 Aug;27(8):669-76.


Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.

Liu B, Huang R, Kuang A, Zhao Z, Zeng Y, Wang J, Tian R.

Med Phys. 2011 Oct;38(10):5412-9. doi: 10.1118/1.3602459.


Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A.

Eur J Nucl Med Mol Imaging. 2010 May;37(5):884-95. doi: 10.1007/s00259-009-1351-2. Epub 2010 Jan 13.


The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A.

Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2298-306. doi: 10.1007/s00259-010-1532-z. Epub 2010 Jul 13.


Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?

Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S.

J Nucl Med. 2005 Feb;46(2):261-6.


Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer.

Upadhyaya A, Meng Z, Wang P, Zhang G, Jia Q, Tan J, Li X, Hu T, Liu N, Zhou P, Wang S, Liu X, Wang H, Zhang C, Zhao F, Yan Z.

Medicine (Baltimore). 2017 Jun;96(25):e7164. doi: 10.1097/MD.0000000000007164.


Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.

Raza H, Khan AU, Hameed A, Khan A.

Nucl Med Commun. 2006 Jun;27(6):495-9.


Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.

Bohuslavizki KH, Klutmann S, Brenner W, Kröger S, Buchert R, Bleckmann C, Mester J, Henze E, Clausen M.

Strahlenther Onkol. 1999 Nov;175 Suppl 4:6-12.


Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.

Bohuslavizki KH, Brenner W, Klutmann S, Hübner RH, Lassmann S, Feyerabend B, Lüttges J, Tinnemeyer S, Clausen M, Henze E.

J Nucl Med. 1998 Jul;39(7):1237-42.


Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.

de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM.

J Nucl Med. 2004 Sep;45(9):1549-54.


Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.

Liu B, Kuang A, Huang R, Zhao Z, Zeng Y, Wang J, Tian R.

J Nucl Med. 2010 Apr;51(4):618-23. doi: 10.2967/jnumed.109.071449. Epub 2010 Mar 17.


Quantification of salivary gland function in thyroid cancer patients treated with radioiodine.

Malpani BL, Samuel AM, Ray S.

Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):535-40.


Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

Bohuslavizki KH, Brenner W, Lassmann S, Tinnemeyer S, Tönshoff G, Sippel C, Wolf H, Clausen M, Henze E.

Nucl Med Commun. 1996 Aug;17(8):681-6.


Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.

Nabaa B, Takahashi K, Sasaki T, Okizaki A, Aburano T.

AJNR Am J Neuroradiol. 2012 Nov;33(10):1964-70. doi: 10.3174/ajnr.A3063. Epub 2012 May 3.


Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.

Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, Vilardell M.

J Nucl Med. 2001 May;42(5):738-43.


Salivary glands ultrasound examination after radioiodine-131 treatment for differentiated thyroid cancer.

Brozzi F, Rago T, Bencivelli W, Bianchi F, Santini P, Vitti P, Pinchera A, Ceccarelli C.

J Endocrinol Invest. 2013 Mar;36(3):153-6. doi: 10.3275/8335. Epub 2012 Apr 5.


Supplemental Content

Support Center